0, the patient was premedicated with diphenhydramine (50 mg) and hydrocortisone (200 mg) i.v., and the first PBSC bag was thawed at 37 1C and infused at a rate of 10 ml/min. Five minutes after the end of the infusion (105 ml; 1.08 Â 10 6 /kg CD34 þ cells), the patient appeared confused and disoriented; soon afterwards, she sequentially developed limb weakness and tetraparesis with symmetric loss of tendon reflexes. After 10 min, she developed a complete loss of consciousness accompanied by mydriasis and urine incontinence, without clonic convulsions or focal neurologic signs. Throughout the entire episode, pulse oxymetry showed adequate saturation, signs of cardiac ischaemia or other electrocardiographic changes, and the patient was normotensive and without arrhythmia. No laboratory abnormalities, including electrolytes, osmolarity, serum glucose and enzymes, were evidenced upon repeated testing. The patient was given hydrocortisone (1000 mg) i.v. and started on forced hydration. She recovered consciousness 1 h after hyperhydration and completely regained motor functions without neuroleptic treatments. However, she was unable to form new memories, and had subtle spell disturbances and appeared anxious and disoriented. This transient global amnaesia-like picture spontaneously and completely resolved after 5 h. The computer-assisted tomography scans and magnetic resonance imaging of brain performed after 24 h were unremarkable, and no further neurological events occurred. No additional PBSC were infused. A single dose (6 mg) of pegfilgrastim was given on day þ 4 and the patient achieved a timely haemopoietic recovery with ANC X500 Â 10 9 /l at day þ 14 and Plts X20 Â 10 9 /l at day þ 16. She received consolidation mediastinal radiotherapy (36 cGy), and clinical reassessment confirmed a persisting CR without problems of late engraftment. At 10 months post-ASCT, the patient remains in CR without any neurological or behavioural sequelae.
Because of the strict temporal relationship between the infusion and development of neurologic symptoms and their resolution upon forced hydration, we circumstantially attribute the encephalopathy to the infusion of 10.5 ml of DMSO contained in the first PBSC bag. Animal model data and clinical observations indicated that this agent may affect the vascular system leading to prolonged vasoconstriction and cerebrovascular ischaemia, [1] [2] [3] [4] [5] 8 even though neuroimaging did not display a 'vascular' pattern in all of the cases (Table 1) . Idiosyncratic mechanisms, a predisposing genetic background and a direct effect of DMSO on neural cell metabolism have also been hypothesized. [5] [6] [7] 9 Whether the occurrence of neurotoxicity is related to the amount of DMSO infused (maximal recommended dose is 1000 mg/kg or 10 ml/kg of a 10% solution) and/or to infusion rate also remains controversial. 7 Our patient developed symptoms after receiving only 10.5 ml of DMSO at a low infusion rate, suggesting that patient-related factors might have also contributed to the development of neurotoxicity.
In our case, at least three factors might have concurred to the neurologic event by sensitizing brain tissues to direct DMSO toxicity. 9 CNS lymphoma involvement might have altered brain cellular milieu, whereas treatment with intrathecal long-acting cytarabine and exposure to high-dose cytarabine (12 g/m 2 over 3 days) could have produced preceding neural cells damage. The short-time interval elapsed from the last intrathecal therapy (76 days), systemic high-dose cytarabine (30 days) and PBSC infusion may have facilitated the neurotoxic action of DMSO. In vitro data have shown that cytarabine-induced neural cells' proapoptotic damage may persist for at least 14 days after treatment ended, with apoptotic rate returning to normal values not before 56 days posttreatment. 10 It is, therefore, conceivable that brain tissues were exposed to DMSO early during postcytarabine neural cell repopulation changes. 10 In some patients experiencing DMSO-associated encephalopathy, altered neuroimaging patterns were localized to the brain stem, hippocampus and thalamus 2,3,5 areas shown to be exquisitely vulnerable to chemotherapy-induced neural cell damage, 10 and among reports detailing preconditioning treatment, the exposure to CNS-penetrating drugs and/or intrathecal therapy was present in five out of eight patients (Table 1) . A large retrospective multicentre evaluation of time intervals elapsed from exposure to CNS-penetrating agents and reinfusion of DMSO-containing products can further validate our hypothesis and eventually patients who would potentially benefit of DMSO-free procedures.
